Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
42 hedge funds and large institutions have $5.61M invested in Viracta Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 6 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0% more funds holding
Funds holding: 42 → 42 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
44% less capital invested
Capital invested by funds: $10.1M → $5.61M (-$4.47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$103K |
| 2 |
Morgan Stanley
New York
|
+$70.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.4K |
| 4 |
Squarepoint
New York
|
+$22.2K |
| 5 |
Renaissance Technologies
New York
|
+$18.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$82.9K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$55K |
| 3 |
Millennium Management
New York
|
-$38K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$25.9K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$19.9K |
VIRX Hedge Fund Activity: Q4 2023 in Review
42 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2023, worth a combined $5.61M — down 44% from $10.1M a quarter earlier.
Fund positioning in VIRX was balanced in Q4 2023: 6 funds opened new positions, 6 closed out, 9 added to existing stakes and 7 trimmed.
The largest buyer was UBS Group, adding an estimated $103K. The largest seller was Laurion Capital Management, cutting an estimated $82.9K.
- 42 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $5.61M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2023, down 44% quarter-over-quarter.
- 6 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2023 and 6 closed out, a net change of 0 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2023 was UBS Group, an estimated $103K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2023 was Laurion Capital Management, an estimated $82.9K sold.
Based on aggregated 13F filings for Q4 2023.